Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
San Diego, United States. In Curr Opin Gastroenterol, Nov 2015
RECENT FINDINGS: We discuss the most important findings of one published phase II trial that targeted the β7 integrin (etrolizumab), two phase II trials that targeted the α4β7 integrin ligand: mucosal addressin cell adhesion molecule 1 (MAdCAM-1, PF-00547659), a phase II trial targeting the chemokine IP-10 (CXCL10) in Crohn's, and a phase II trial that targeted the sphingosine-1-phosphate receptor-1: ozanimod in patients with ulcerative colitis.
[Vedolizumab in the treatment of Crohn's disease].
Madrid, Spain. In Gastroenterol Hepatol, May 2015
Vedolizumab is a humanized monoclonal antibody that binds specifically to the α4β7 integrin, inhibiting T lymphocytes from binding to adhesion molecules (MAdCAM-1), which are expressed mainly in the small bowel and colon.
Review article: anti-adhesion therapies for inflammatory bowel disease.
Leuven, Belgium. In Aliment Pharmacol Ther, 2014
RESULTS: A total of eight drugs were found including those targeting the α4β1, α4β7 or αEβ7 integrins as well as the ICAM-1 and MAdCAM-1 addressins and the chemokine receptor 9. The rationale for these drugs is the blockade of gut-homing T lymphocytes and the ones targeting the α4β7/MAdCAM-1 interaction presented the most promising results in luminal disease.
Effect of dietary fat on intestinal inflammatory diseases.
Tokorozawa, Japan. In J Gastroenterol Hepatol, 2013
Enhanced infiltration of leukocytes and expression of mucosal addressin cell adhesion molecule-1 in intestinal mucosa was significantly decreased by omega-3 fat-rich diets treatment.